Mirtazapin Actavis (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action raises serotonin and norepinephrine levels while reducing certain serotonergic side‑effects, producing an antidepressant effect.

The appropriate dose of Mirtazapin Actavis is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and tolerability. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for mirtazapine in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and its excretion in breast milk is not well defined. Use only if the potential benefit justifies the potential risk, and discuss alternatives with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Mirtazapin Actavis belongs to the NaSSA class, which differs from SSRIs and SNRIs by its combined α2‑adrenergic antagonism and selective serotonin receptor blockade. This profile often results in pronounced sedative and appetite‑stimulating effects, making it useful for patients with insomnia or weight loss, whereas other antidepressants may have different side‑effect patterns.

Mirtazapin Actavis should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Mirtazapin Actavis is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed, unless a prescriber provides specific instructions for an alternative method.

Serious risks include the potential for agranulocytosis, severe neutropenia, Stevens‑Johnson syndrome, and the emergence of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for signs of infection, skin reactions, or worsening mood, and seek immediate medical attention if such symptoms appear.

Mirtazapin Actavis is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate manic episodes.